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Abstract 
Background: Depression and anxiety are common in inflammatory bowel disease (IBD) and can affect disease out‑
comes, including quality of life and success of disease treatment. Successful management of psychiatric comorbidities 
may improve outcomes, though the effectiveness of existing treatments in IBD is unknown.
Methods: We searched multiple online databases from inception until March 25, 2015, without restrictions on 
language, date, or location of publication. We included controlled clinical trials conducted in persons with IBD and 
depression or anxiety. Two independent reviewers reviewed all abstracts and full‑text articles and extracted informa‑
tion including trial and participant characteristics. We also assessed the risk of bias.
Results: Of 768 unique abstracts, we included one trial of pharmacological anxiety treatment in IBD (48 participants), 
which found an improvement in anxiety symptoms (p < 0.001). There was a high risk of bias in this trial. We found no 
controlled clinical trials on the treatment of depression in persons with IBD and depression and no controlled clinical 
trials reporting on psychological interventions for anxiety or depression in IBD.
Conclusions: Only one trial examined an intervention for anxiety in adults with IBD and no trials studied depression 
in adults with IBD. The level of evidence is low because of the risk of bias and limited evidence.
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Background
Inflammatory bowel disease (IBD) is a chronic immune-
mediated inflammatory disease of the gastrointestinal 
tract, affecting at least 1 million Americans and 2.5 mil-
lion Europeans [1]. IBD emerges in children, but the peak 
age of onset is in the third and fourth decades [2–4]. 
Hence, this disease impacts affected individuals in the 
prime of their lives from social and work perspectives, 
and is associated with considerable disability [5–7].
There is a high prevalence of depression and anxiety 
disorders in persons with IBD; over 25 % of individuals 
with IBD will experience depression in their lifetime, 
while anxiety may affect more than 30  % [8]. Psychiat-
ric comorbidity is associated with adverse outcomes in 
IBD. Depression is associated with an increased risk of 
disease relapse in IBD, [9] and is a risk factor for treat-
ment failure with infliximab [10]. By managing depres-
sion and anxiety in persons with IBD outcomes may be 
improved, but it is unclear if treatments for depression 
and anxiety that are effective in the general population 
would be similarly effective in persons with IBD. Com-
monly used pharmacological treatments for depres-
sion and anxiety may be less effective in those who use 
anti-inflammatory therapies, [11] or lead to potentially 
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harmful adverse effects or exacerbations in symptoms 
[12].
The objective of this systematic review was to identify 
the existing literature on controlled clinical trials of phar-
macological and psychological interventions for depres-
sion and anxiety in persons with IBD.
Methods
We conducted this systematic review according to the 
approach described in the Cochrane Handbook for Sys-
tematic Reviews, [13] using an a priori published protocol 
[14]. We report the findings according to the preferred 
reporting items for systematic reviews and meta-analyses 
(PRISMA) criteria [15].
Populations, interventions, comparators, settings 
and study designs
Trials were included if conducted in persons with IBD who 
were depressed and/or anxious. IBD was defined according 
to the criteria reported in each paper. Controlled clinical tri-
als (i.e. randomized controlled trials (RCT), controlled before 
and after trials) conducted in any clinical setting were eligi-
ble. Diagnoses of depression or anxiety could be based on 
self-report using a screening tool or a clinical interview. We 
examined the methods used by individual papers to identify 
the study populations, including the tools used, and there 
were no other pre-specified criteria regarding the definition 
of depression or anxiety. If the entire sample was <18 years 
old trials were excluded to reduce heterogeneity.
Outcome measures
Our primary research question was: “What is the effi-
cacy of pharmacological and psychological treatments 
for depression or anxiety in persons with IBD”. We 
included the following secondary outcomes based on 
recommendations from primary care providers and indi-
viduals living with IBD: (1) difference in fatigue scores 
at post-assessment between the treatment and com-
parison groups; (2) difference in quality of life scores at 
post-assessment between the treatment and compari-
son groups; (3) the proportion of participants achiev-
ing ≥50 % reduction in depressive or anxiety symptoms 
from baseline to post-assessment between the treatment 
and control. In all cases post-assessment was the longest 
reported follow-up.
The final research question: “What is the tolerability of 
pharmacotherapy for depression or anxiety in IBD?”, was 
examined according to the dose and duration of the treat-
ment, drop-out rates, and any reported adverse effects.
Search strategy
We developed our search strategy (Additional file  1: 
Appendix) with the help of a medical librarian (MF), and 
experts in gastrointestinal disease (CNB) and psychi-
atric disorders (SBP, JW, LG, KMF, JS, JB). We searched 
the Cochrane Database of Systematic Reviews and the 
following databases: Medline, EMBASE, PsycINFO, 
PsycARTICLES Full Text, Cochrane Central Register of 
Controlled Trials, CINAHL, Web of Science, and Sco-
pus to identify RCTs and related systematic reviews. We 
searched Clinicaltrials.gov and the WHO trial register to 
identify completed or ongoing trials. We also searched 
the reference lists of related systematic reviews and of 
the included trials to identify any further studies. There 
were no date or language limits placed on the searches. 
We searched databases from inception date to March 25, 
2015. The Cochrane Highly Sensitive Search Strategy was 
employed in MEDLINE, and variations of this filter, or 
other validated filters, were used for other databases.
Study selection process
EPPI-Reviewer [16] was employed for the two-phase title 
and abstract review by two independent reviewers (KMF 
and RAM). We reviewed titles and abstracts in the first 
phase to determine if they were conducted in individu-
als with IBD and who had depression or anxiety. In the 
second phase, these abstracts were determined to be 
controlled clinical trials or not. Following the two-phase 
review, the full-text articles were reviewed in detail by 
the same reviewers to ensure all inclusion criteria were 
met, and disagreements were resolved by discussion.
Data extraction and management
We completed data extraction in duplicate using a data 
collection tool developed by the author team and imple-
mented in EPPI-Reviewer. Information on study design, 
inclusion criteria for the study population, including 
demographic or disease characteristics (e.g. age, sex, 
disease subtype, race/ethnicity), methods for identify-
ing psychiatric comorbidity (e.g. diagnostic interview, 
self-report questionnaire) including the tools used, 
interventions employed, items related to the risk of bias 
assessment (see below), and any efficacy or safety out-
comes was collected.
Risk of bias assessment and grading the evidence
Two reviewers independently evaluated the internal 
validity of the trials using the Cochrane Collaboration’s 
Risk of Bias tool [17], which evaluates risk of bias in six 
domains: sequence generation, allocation concealment, 
masking/blinding of participants, personnel, and out-
come assessors, incomplete outcome data, selective out-
come reporting, and other sources of bias. Each domain 
is rated as having either a low risk of bias, unclear risk of 
bias, or high risk of bias. The overall assessment is based 
on responses to individual domains; the overall score was 
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rated as having a high risk of bias if one or more individ-
ual domains is assessed as having a high risk of bias. Only 
if all components are rated as having a low risk of bias 
is the overall risk rated as low. Risk of bias for all other 
studies was rated as unclear. Disagreements on the bias 
assessment were resolved by discussion. The approach 
described by the GRADE working group was used to 
determine the strength of the evidence: low, moderate, or 
high [18].
Data synthesis and analysis
We used descriptive statistics, including frequencies 
(reported as a percent), to summarize the study findings.
Results
Results of the search
We screened 768 unique abstracts, initially excluding 
733. Over 50  % (399/733) were excluded because they 
were not conducted in a population of persons with IBD, 
almost 29  % (210/733) were excluded as the study pop-
ulation did not have depression or anxiety, while 16  % 
(117/733) were excluded as they did not study depres-
sion or anxiety, and the final abstracts were excluded 
because they were duplicates (Fig. 1). A second abstract 
review was completed where a further 17 abstracts were 
excluded because they were not controlled clinical tri-
als; others were excluded as they were not conducted in 
a population with depression or anxiety. We reviewed 
the full-text of 11 published manuscripts. Of these, one 
article met the final inclusion criteria for the review 
(Table 1).
Description of trials
A single American RCT of the treatment of anxiety in 
48 persons with IBD was published in 1978 [19]. This 
trial assessed the effect of a pharmacological interven-
tion (lorazepam) administered by a gastroenterologist, 
and was performed in a specialty clinic (Table  1). No 
trial of depression in IBD was identified. No controlled 
clinical trials of psychological interventions for anxiety or 
depression in IBD were found.
Interventions and assessments
The sole trial of anxiety used the Hamilton and the 
Global to determine participant eligibility. The active 
treatment phase of this trial was 4  weeks, and par-
ticipants received either lorazepam (1  mg before noon, 
2  mg at bedtime) or placebo. The Hamilton Scale and 
Global were also used to assess changes in anxiety symp-
toms over time.
Risk of bias assessment
The single included IBD trial had a high risk of bias, as 




Depression was not reported as an outcome.
Anxiety
In the one trial of pharmacological anxiety treatment in 
IBD, anxiety scores improved between visits in the inter-
vention group (SMD could not be calculated- treatment 
group mean change score: 9.2 [standard error (SE): 1.5]; 
placebo group mean change score: 4.0 (SE: 1.1); p < 0.01).
Strength of evidence
Single RCT was rated as providing moderate evidence, 
but we downgraded the overall strength of evidence to 
low because in the presence of one trial uncertainty per-
sists regarding the true effect (Additional file 3).
Secondary outcomes
We were unable to assess any of the secondary outcomes 
related to fatigue and quality of life because they were not 
assessed in the single included trial.
Tolerability
Reported adverse medication effects were numerous in 
both the treatment and comparison groups (Additional 
file 4). The most common adverse events in the treatment 
group were unsteadiness/incoordination (11.5  %) and 
dizziness, headache, sedation, dermatological symptoms, 
or gastrointestinal symptoms (each 7.7  %). In the com-
parison group dizziness, headache, sleep disturbance, 
nausea, and vomiting were equally common (each 4.5 %). 
The dropout rate in the treatment group was 7.7 % and in 
the comparison group 4.5 %.
Discussion
In our systematic review of the literature, we found no 
trials reporting on interventions for depression in IBD, 
and only a single RCT reporting on an intervention for 
anxiety. This trial reported a statistically significant 
reduction in anxiety symptoms following pharmacologi-
cal intervention. The trial did not report on the effects of 
the intervention on fatigue, pain or quality of life.
Depression and anxiety are highly prevalent in IBD [8] 
and can have detrimental effects on IBD disease course 
and quality of life. In persons with Crohn’s disease, 
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depression or generalized anxiety disorder may be asso-
ciated with an increased risk of surgery [20]. In a broader 
IBD population, depressive symptoms were associated 
with an increased number of relapses and with a shorter 
time to first relapse, while anxiety and reduced quality of 
life were associated with more frequent relapses [9]. In 
both ulcerative colitis and Crohn’s disease, depression 
has been associated with clinical disease recurrence; dis-
ease recurrence may also be associated with symptoms 
of anxiety in persons with Crohn’s disease [21]. In active 
Crohn’s disease, depression is associated with a failure 
to achieve remission on infliximab and earlier retreat-
ment [10]. Regardless of disease severity, the presence of 
psychiatric comorbidities in IBD may contribute to poor 
quality of life [22].
Psychiatric comorbidities can be successfully managed 
in chronic inflammatory conditions, [23] and as such 
may be a means of improving outcomes in persons with 
IBD. Despite this, depression and anxiety disorders are 
under-recognized and undertreated in persons with IBD; 
one study estimated that of 43 % of persons with symp-
toms of depression or anxiety, only 18 % of those people 
were receiving psychological treatment and 21  % were 
taking psychotropic medications [24]. As a first step to 
improved management, improved detection of depres-
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The anxiety screening tools used (Hamilton and the 
Global) have not been validated for use in persons with 
IBD. It is imperative that depression and anxiety screen-
ing tools be validated in disease-specific settings to 
ensure scale performance is adequate, investigate poten-
tial confounding effects, including those of somatic 
symptoms, and assess the optimal scoring criteria. In 
other chronic diseases such as multiple sclerosis and 
rheumatoid arthritis, it has been suggested that the inclu-
sion of physical symptoms of the disease (e.g. tingling, 
dizziness) in psychiatric screening tools may lead to 
“criterion contamination” [25–27]. This contamination 
results from an overlap in disease-specific and anxiety 
symptoms, which may cause people to screen positive for 
anxiety (i.e. an increase in false positives) when the anxi-
ety symptoms are due to the disease itself. These screen-
ing tools may also perform differently in persons with 
IBD than the general population (due to criterion con-
tamination, common pathophysiology such as inflam-
mation [28]), and scoring cutpoints appropriate for IBD 
must be established.
Controlled clinical trials that did not have depression 
or anxiety as inclusion criteria and those with only gen-
eral education approaches regarding IBD were excluded 
from this review. In a recent RCT, both CBT and sup-
portive nondirective therapy significantly reduced 
depressive symptoms and improved global functioning, 
quality of life, and disease activity in 178 adolescents with 
depression and Crohn’s disease or ulcerative colitis [29]. 
In addition, the ongoing HAPPY-IBD trial assesses the 
impact of IBD-specific CBT on subsyndromal symptoms 
of depression or anxiety in adolescents with IBD [30]. 
These trials of adolescents may provide insight into the 
design and conduct of future trials in adults with IBD.
To determine the efficacy of psychosocial or pharmaco-
logical interventions for reducing clinical anxiety or depres-
sion in persons with IBD, RCTs must be appropriately 
designed, including targeting the appropriate population. 
Participants should meet diagnostic criteria for anxiety or 
mood disorders using validated measurement tools. Tools 
used to measure anxiety and depression outcomes should 
be shown to be valid, reliable, and sensitive to change in 
IBD before being employed in a trial of this population. 
Given the potentially broad effects of psychiatric comor-
bidity on outcomes in IBD, such trials should also include 
outcomes related to IBD disease activity, and patient-cen-
tred outcomes such as pain, fatigue, and quality of life.
This review was conducted according to established 
systematic review methodology using a registered proto-
col, searching multiple databases with limited publication 
restrictions. The conclusions in this paper are limited 
by the nature of the available literature: only one study 
met all inclusion criteria, and was of strength and risk of 
bias. The included study was published almost 40  years 
ago and conceptions of IBD and psychiatric disorders 
have changed greatly since that time. All relevant out-
comes (quality of life, fatigue, disease activity, etc.) must 
be examined in future trials of treatments for depression 
or anxiety in IBD, as existing evidence suggests that they 
have a substantial impact on functioning.
Conclusions
There is a dearth of evidence regarding treatment of 
depression or anxiety in persons with IBD. Considering 
the prevalence and impact these psychiatric comorbidi-
ties can have on the outcome of IBD, intervention trials 
in this area are desperately needed.
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